Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

DM, Fleming; P, Crovari; U, Wahn; T, Klemola; Y, Schlesinger; A, Langussis; K, Øymar; ML, Garcia; A, Krygier; H, Costa; U, Heininger; JL, Pregaldien; SM, Cheng; J, Skinner; A, Razmpour; M, Saville; WC, Gruber; B, Forrest

doi:10.1097/01.inf.0000237797.14283.cf

Public

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Shared by NobleBlocks on Oct 1, 2006 • 12:00 AM UTC

Authors:

Fleming DM

Crovari P

Wahn U

Abstract

Background Despite their potential for increased morbidity, 75% to 90% of asthmatic children do not receive influenza vaccination. Live attenuated influenza vaccine (LAIV), a cold-adapted, temperature-sensitive, trivalent influenza vaccine, is approved for prevention of influenza in healthy children...

Discussions